Tear Interleukin Biomarkers After Glaucoma Treatment

This prospective study aims to evaluate inflammatory biomarkers in tear fluid in patients with glaucoma undergoing micropulse transscleral cyclophotocoagulation (MP-CPC), continuous-wave cyclophotocoagulation (CPC), and antiglaucoma surgeries. The study will assess the concentrations of pro- and anti-inflammatory interleukins in tear samples collected before treatment, 5-7 days after the procedure, and 1 month postoperatively. Intraocular pressure (IOP) will be measured at the same time points. The correlation between changes in interleukin levels and IOP reduction will be analyzed. Additionally, the study aims to compare inflammatory response patterns among the MP-CPC, CPC, and surgical treatment groups and to identify interleukin profiles associated with a clinically significant hypotensive effect.

Inclusion Criteria: * Decision to treat by MP-CPC Laser * Patients diagnosed with Glaucoma * Patients aged 18 years old and above * Glaucoma that is inadequately controlled on medical therapy Exclusion Criteria: * Patients age less than 18 years * Patients unable or unwilling to provide informed consent to participate in the study * Patients potentially unavailable for follow up visits * Patients with significant scleral thinning * Patients with ocular infection, inflammation or intraocular surgery in the study eye 2 months prior to enrollment in the study * Albino patients that have no iris pigmentation